CADTH Canadian drug expert committee recommendation: Inotersen (Tegsedi -- Akcea Therapeutics, Inc.) indication : treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR)
The CADTH Canadian Drug Expert Committee recommends that inotersen be reimbursed for the treatment of polyneuropathy in adult patients with hATTR, only if the following conditions are met : Conditions for reimbursement, initiation criteria 1. Confirmed genetic diagnosis of hATTR. 2. Patients who hav...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
December 20, 2019, 2019
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee recommends that inotersen be reimbursed for the treatment of polyneuropathy in adult patients with hATTR, only if the following conditions are met : Conditions for reimbursement, initiation criteria 1. Confirmed genetic diagnosis of hATTR. 2. Patients who have all of the following characteristics: 2.1 Are symptomatic with early-stage neuropathy, defined as 2.1.1 Polyneuropathy disability stage I to ≤ IIIB, or 2.1.2 Familial amyloidotic polyneuropathy stage I or II. 2.2 Do not exhibit severe heart failure symptoms (defined as New York Heart Association class III or IV). 2.3 Have not previously undergone a liver transplant. 3. Inotersen should not be used in combination with other interfering ribonucleic acid drugs or transthyretin stabilizers used to treat hATTR. |
|---|---|
| Physical Description: | 1 PDF file (9 pages) |